A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline

Michael Berney, Travis E. Hartman, William R. Jacobs

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The new medicinal compound bedaquiline (BDQ) kills Mycobacterium tuberculosis by inhibiting F1Fo-ATP synthase. BDQ is bacteriostatic for 4 to 7 days and kills relatively slowly compared to other frontline tuberculosis (TB) drugs. Here we show that killing with BDQ can be improved significantly by inhibiting cytochrome bd oxidase, a non-proton-pumping terminal oxidase. BDQ was instantly bactericidal against a cytochrome bd oxidase null mutant of M. tuberculosis, and the rate of killing was increased by more than 50%. We propose that this exclusively bacterial enzyme should be a high-priority target for new drug discovery.

IMPORTANCE A major drawback of current TB chemotherapy is its long duration. New drug regimens with rapid killing kinetics are desperately needed. Our study demonstrates that inhibition of a nonessential bacterial enzyme greatly improves the efficacy of the latest TB drug bedaquiline and emphasizes that screening for compounds with synergistic killing mechanisms is a promising strategy.

Original languageEnglish (US)
Article numbere01275-14
JournalmBio
Volume5
Issue number4
DOIs
StatePublished - Jul 15 2014

Fingerprint

bedaquiline
Electron Transport Complex IV
Mycobacterium tuberculosis
Tuberculosis
Pharmaceutical Preparations
Enzymes
Drug Discovery
Oxidoreductases
Adenosine Triphosphate
Drug Therapy

ASJC Scopus subject areas

  • Microbiology
  • Virology

Cite this

A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. / Berney, Michael; Hartman, Travis E.; Jacobs, William R.

In: mBio, Vol. 5, No. 4, e01275-14, 15.07.2014.

Research output: Contribution to journalArticle

@article{fcb6b8d21af94b0cba705988958b6b2e,
title = "A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline",
abstract = "The new medicinal compound bedaquiline (BDQ) kills Mycobacterium tuberculosis by inhibiting F1Fo-ATP synthase. BDQ is bacteriostatic for 4 to 7 days and kills relatively slowly compared to other frontline tuberculosis (TB) drugs. Here we show that killing with BDQ can be improved significantly by inhibiting cytochrome bd oxidase, a non-proton-pumping terminal oxidase. BDQ was instantly bactericidal against a cytochrome bd oxidase null mutant of M. tuberculosis, and the rate of killing was increased by more than 50{\%}. We propose that this exclusively bacterial enzyme should be a high-priority target for new drug discovery.IMPORTANCE A major drawback of current TB chemotherapy is its long duration. New drug regimens with rapid killing kinetics are desperately needed. Our study demonstrates that inhibition of a nonessential bacterial enzyme greatly improves the efficacy of the latest TB drug bedaquiline and emphasizes that screening for compounds with synergistic killing mechanisms is a promising strategy.",
author = "Michael Berney and Hartman, {Travis E.} and Jacobs, {William R.}",
year = "2014",
month = "7",
day = "15",
doi = "10.1128/mBio.01275-14",
language = "English (US)",
volume = "5",
journal = "mBio",
issn = "2161-2129",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline

AU - Berney, Michael

AU - Hartman, Travis E.

AU - Jacobs, William R.

PY - 2014/7/15

Y1 - 2014/7/15

N2 - The new medicinal compound bedaquiline (BDQ) kills Mycobacterium tuberculosis by inhibiting F1Fo-ATP synthase. BDQ is bacteriostatic for 4 to 7 days and kills relatively slowly compared to other frontline tuberculosis (TB) drugs. Here we show that killing with BDQ can be improved significantly by inhibiting cytochrome bd oxidase, a non-proton-pumping terminal oxidase. BDQ was instantly bactericidal against a cytochrome bd oxidase null mutant of M. tuberculosis, and the rate of killing was increased by more than 50%. We propose that this exclusively bacterial enzyme should be a high-priority target for new drug discovery.IMPORTANCE A major drawback of current TB chemotherapy is its long duration. New drug regimens with rapid killing kinetics are desperately needed. Our study demonstrates that inhibition of a nonessential bacterial enzyme greatly improves the efficacy of the latest TB drug bedaquiline and emphasizes that screening for compounds with synergistic killing mechanisms is a promising strategy.

AB - The new medicinal compound bedaquiline (BDQ) kills Mycobacterium tuberculosis by inhibiting F1Fo-ATP synthase. BDQ is bacteriostatic for 4 to 7 days and kills relatively slowly compared to other frontline tuberculosis (TB) drugs. Here we show that killing with BDQ can be improved significantly by inhibiting cytochrome bd oxidase, a non-proton-pumping terminal oxidase. BDQ was instantly bactericidal against a cytochrome bd oxidase null mutant of M. tuberculosis, and the rate of killing was increased by more than 50%. We propose that this exclusively bacterial enzyme should be a high-priority target for new drug discovery.IMPORTANCE A major drawback of current TB chemotherapy is its long duration. New drug regimens with rapid killing kinetics are desperately needed. Our study demonstrates that inhibition of a nonessential bacterial enzyme greatly improves the efficacy of the latest TB drug bedaquiline and emphasizes that screening for compounds with synergistic killing mechanisms is a promising strategy.

UR - http://www.scopus.com/inward/record.url?scp=84908226003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908226003&partnerID=8YFLogxK

U2 - 10.1128/mBio.01275-14

DO - 10.1128/mBio.01275-14

M3 - Article

C2 - 25028424

AN - SCOPUS:84908226003

VL - 5

JO - mBio

JF - mBio

SN - 2161-2129

IS - 4

M1 - e01275-14

ER -